Lobeline for smoking cessation

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2012, Pages

  Stead, Lindsay F ^a   Hughes, John R ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOBELINE; PLACEBO; NICOTINIC RECEPTOR BLOCKING AGENT;

CLINICAL EFFECTIVENESS; DRUG EFFICACY; FOLLOW UP; HUMAN; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW; METHODOLOGY;

HUMANS; LOBELINE; NICOTINIC ANTAGONISTS; SMOKING; SMOKING CESSATION;

EID: 84861305133     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000124.pub2     Document Type: Review

References (44)

1. Bachman DS. Group smoking deterrent therapy. GP 1964;30:86.
2. Bartlett WA, Whitehead RW. The effectiveness of meprobamate and lobeline as smoking deterrents. Journal of Laboratory and Clinical Medicine 1957;50(2):278-81.
3. British Tuberculosis Association Research Committee. Smoking deterrent study. British Medical Journal 1963;2:486-7.
4. Davison GC, Rosen RC. Lobeline and reduction of cigarette smoking. Psychological Reports 1972;31:443-56.
5. Dorsey JL. Control of the tobacco habit. Annals of Internal Medicine 1936;10:628-31.
6. Edwards G. Double-Blind Trial of Lobeline in an Anti-Smoking Clinic. Medical Officer 1964;112:158-60.
7. Edwards G. Hypnosis and lobeline in an Anti-Smoking Clinic. Medical Officer 1964;111:239-43.
8. Ejrup B. Follow-up of the material of smokers difficult to treat. Svenska Läkartidningen 1959;56:2254-62.
9. Ejrup B. Fortsatta forsok till avvanjing fran toback medelst injektions behandling. Svenska Läkartidningen 1959;56:1975-86.
10. Ejrup B. Report to American Cancer Society Conference of Experts on Ways to help people give up smoking. New York City. 19-20 Dec 1967.
11. Farago I. Results of a weaning cure of 1125 smokers. Contribution to the nicotine addiction problem [Ergebnisse der entwohnungskuren von 1125 rauchern:beitrag zum nikotinsucht-problem]. Schweizer Archiv fur Neurologie Neurochirurgie und Psychiatrie 1968;102:167-89.
12. Glover ED, Leischow SJ, Rennard SI, Glover PN, Daughton D, Quiring JN, et al. A smoking cessation trial with lobeline sulfate: A pilot study. American Journal of Health Behavior 1998;22:62-74.
13. Schneider FH, Olsson TA. Clinical experience with lobeline as a smoking cessation agent. Medicinal Chemistry Research 1996;6:562-70.
14. DynaGen Inc. NicErase-SL multi-center phase 3 trial shows efficacy in one of three sites. Press Release 29 August 1997.
15. Glover ED, Rath JM, Sharma E, Glover PN, Laflin M, Tonnesen P, et al. A multicenter phase 3 trial of lobeline sulfate for smoking cessation. American Journal of Health Behavior 2010;34:101-9.
16. Golledge AH. Influencing factors in ant-smoking clinics together with the results of a double blind trial of Lobidan. Medical Officer 1965;114:59-61.
17. Graff H, Hammet VO, Bash N, Fackler G, Yanovski A, Goldman A. Results of four antismoking methods. Pennsylvania Medical Journal 1966;69:86-9.
18. Hoffstaedt EGW, Pearson RCM. The experimental smokers' advisory clinic Newcastle upon Tyne. Medical Officer 1964;111(31 Jan):59-60.
19. Hoffstaedt EGW. The treatment of the unwilling smoker. A clinical approach. Practitioner 1965;195:794-8.
20. Jacobs MA, Spilken AZ, Norman MM, Wohlberg GW, Knapp PH. Interaction of personality and treatment conditions associated with success in a smoking control program. Psychosomatic Medicine 1971;33:545-56.
21. Jochum K, Jost F. Nicotine addiction and its treatment. Münchener Medizinische Wochenschrift 1961;103:618-22.
22. Kalyuzhny VV. The treatment of tobacco smoking by means of lobeline and the effect of lobeline on vegetative and vascular reactions. Zh Nevropatol Psikhiatr 1968;68:1864-70.
23. Kaufman H, Bensimon L. Tobacco withdrawal [Le sevrage du tabac]. Vie Medicale 1960;41:1139.
24. Leone LA, Musiker HR, Albala MM, McGurk W. A study of the effectiveness of the smoking deterrence clinic. Rhode Island Medical Journal 1968;51:247-257, 260.
25. London SJ. Clinical evaluation of a new lobeline smoking deterrent. Current Therapeutic Research 1963;5(4):167-75.
26. McChargue DE, Collins FL, Cohen LM. Effect of non-nicotinic moist snuff replacement and lobeline on withdrawal symptoms during 48-h smokeless tobacco deprivation. Nicotine & Tobacco Research 2002;4(2):195-200.
27. Merry J, Preston G. The effect of buffered lobeline sulphate on cigarette smoking. Practitioner 1963;190:628-31.
28. Perlstein IB. Smoking deterrent therapy in private practice. The first M.R. Thompson Symposium on recent advances in the medical aspects of smoking. New York: Matthew Publishing Co, 1964:40-5.
29. Rapp GW, Olen AA. A critical evaluation of a lobeline based smoking deterrent. American Journal of Medical Science 1955;230:9-14.
30. Rapp GW, Dusza BT, Blanchet L. Absorption and utility of lobeline as a smoking deterrent. American Journal of Medical Science 1959;237:287-92.
31. Rosenberg A. Attempt at stopping the tobacco habit. Ugeskrift for Laeger 1959;121:881-6.
32. Rosnick MJ. The smoking deterrent effect of a new lobeline dosage form. Journal of the Florida Medical Association 1965;52:27-30.
33. Ross CA. Smoking withdrawal research clinics. American Journal of Public Health 1967;57:677-81.
34. Schneider FH, Olsson TA. Clinical experience with lobeline as a smoking cessation agent. Medicinal Chemistry Research 1996;6:562-70.
35. Schneider FH, Mione PJ, Raheman FS, Phillips BM, Quiring JN. Reduction of tobacco withdrawal symptoms by sublingual lobeline sulfate. American Journal of Health Behavior 1996;20:346-63.
36. Scott GW, Cox AGC, MacLean KS, Price TML, Southwell N. Buffered lobeline as a smoking deterrent. Lancet 1962;279(7219):54-5.
37. Swartz H, Cohen A. Clinical evaluation of SmoKurb as a smoking deterrent. Current Therapeutic Research 1964;6(4):290-6.
38. Wright IS, Littauer D. Lobeline sulphate: its pharmacology and use in the treatment of the tobacco habit. JAMA 1937;109:649-654.
39. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD006103.pub5]
40. Department of Health and Human Services, Food, Drug Administration. Smoking deterrent drug products for Over-the-Counter human use. FR 31236 1 June 1993; Vol. 58, issue 103.
41. Schwartz JL. A critical review and evaluation of smoking control methods. Public Health Reports 1969;84:483-506.
42. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD000146.pub3]
43. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al. Placebo-controlled trial of cytisine for smoking cessation. 2011. New England Journal of Medicine 2011;365:1193-1200.
44. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Disease 1985;27(5):335-71.